SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to offer pre-IPO exposure to SpaceX, with many community members labeling it a scam and warning against potential pump-and-dump schemes. While participants look for ways to gain exposure to the rumored SpaceX IPO through related stocks and space-sector ETFs, experts emphasize that official equity is not currently available to the public.

Fartcoin is a meme-driven cryptocurrency where users can submit their best fart jokes or memes to earn initial tokens. Each transaction triggers a hilarious 'Gas Fee' effect, complete with a digital fart sound for maximum comedic impact.

Fartcoin

Fartcoin is seeing intense community engagement as investors debate its potential for a major breakout, with the conversation dominated by meme-centric hype, speculative price predictions, and comparisons to other viral meme tokens. The discussion remains polarized between bullish sentiment fueled by historical price action and skepticism regarding the long-term utility of the project.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending as the community debates Bitcoin's long-term trajectory and institutional adoption, with sentiment split between long-term bullish holders betting on cyclical gains and short-term traders warning of potential volatility as BTC faces resistance levels. Investors are actively discussing the impact of broader economic indicators, regulatory shifts, and leverage trends on the asset's momentum.

Investment Managers Series Trust II - Tradr 2X Long AAOI Daily ETF

The Tradr 2X Long AAOI Daily ETF

AAOX is generating significant community conversation as a leveraged vehicle for traders looking to amplify their exposure to the volatile price action in Applied Optoelectronics. Investors are actively debating the merits of this high-risk tool, focusing on its use for short-term momentum plays and potential short squeezes within the broader optical networking and AI-related tech sector.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is trending as investors debate the potential of its DePin infrastructure and long-term utility against persistent frustration over its history of pump-and-dump price action. Community sentiment remains deeply polarized, with many users expressing skepticism over past broken promises and project leadership while others aggressively accumulate, citing bullish signals and upcoming ecosystem developments.

Vanguard World Fund - Vanguard Energy ETF

Vanguard Energy ETF

Vanguard Energy ETF (VDE) is trending as investors react to high energy prices, geopolitical tensions in the Middle East, and ongoing concerns regarding global supply chain disruptions. Community members are actively debating the long-term growth potential of energy assets amidst persistent inflationary pressures and shifting supply-demand dynamics.

Canadian Natural Resources Ltd. is an oil and natural gas production company, which engages in the exploration, development, marketing, and production of crude oil and natural gas. It operates through the following segments: Oil Sands Mining & Upgrading, Midstream & Refining, and Exploration & Production. The Oil Sands Mining & Upgrading segment produces synthetic crude oil through bitumen mining and upgrading operations. The Midstream & Refining segment focuses on maintaining pipeline operations and investment. The Exploration & Production segment consists of operations in North America, largely in Western Canada, the United Kingdom portion of the North Sea, and Côte d’Ivoire and South Africa in Africa. The company was founded on November 7, 1973 and is headquartered in Calgary, Canada.

Canadian Natural Resources Ltd.

Canadian Natural Resources is trending as investors highlight its resilient oil sands production, consistent dividend growth streak, and strong cash flow generation despite broader market volatility. The community remains focused on the company's status as a top-tier energy producer, emphasizing its long-term value and operational efficiency in an evolving energy landscape.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is capturing intense retail attention as investors bet on its potential to challenge the domestic supply chain for rare earth magnets. The community is focused on the stock's low-float, volatile trading patterns, with active discussions debating whether its tech-integrated mining approach is a legitimate long-term play or a short-term pump and dump.

Global X Funds - Global X DAX Germany ETF

Global X DAX Germany ETF

The Global X DAX Germany ETF is actively discussed by traders utilizing Elliott Wave and high-frequency technical analysis to identify potential entry points within cycles. Community members are closely tracking key structure pivots, debating bullish setups for the index while closely monitoring broader European economic and geopolitical signals that often influence global index momentum.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as investors digest a massive $7.1 billion charge related to a strategic pivot away from North American electric vehicle expansion and China operations. The company is reallocating capital toward profitable truck and SUV segments to secure near-term cash flow, drawing intense community debate over whether this represents a disciplined operational reset or a failure of the long-term EV transition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.</li><li>The agency stated that it has also cleared DemeRx NB’s early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug submission.</li><li>Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.</li></ul>The U.S. Food and Drug Administration (FDA) on Friday announced several regulatory actions to accelerate the development of psychedelic treatments aimed at serious mental health issues.The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.“Under President Trump’s leadership, we are accelerating the research, approval, and responsible access to promising mental health treatments—including psychedelic therapies like ibogaine—to confront our nation’s mental health crisis head-on, especially for our veterans,” said Health and Human Services Secretary Robert F. Kennedy, Jr.This comes after President Trump signed an executive order last week that directed health agencies to speed up research on drugs like psilocybin, MDMA, and ibogaine.Shares of&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) skyrocketed over 62% in Friday morning’s trade, while&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass Pathways Plc.</a> (CMPS) and&nbsp;<a href="https://stocktwits.com/symbol/HELP">Helus Pharma Inc.</a> (HELP) and&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences Inc.</a> (ENVB) rose between 2% to 3%.<h2 class="st-heading-2">FDA To Issue National Priority Vouchers</h2>The FDA stated that it will issue national priority vouchers to three companies studying psilocybin for the treatment of treatment-resistant depression and major depressive disorder, and methylone for the treatment of PTSD.Compass Pathways announced that it has been awarded a national priority voucher for COMP360, its proprietary formulation of synthetic psilocybin for treatment-resistant depression.The agency stated that it has also cleared an early-stage clinical trial of noribogaine hydrochloride for potential treatment of alcohol use disorder to proceed following an Investigational New Drug (IND) submission.This is the first time the FDA has permitted a U.S.-based clinical study of an ibogaine derivative, enabling the developer of the novel therapy, DemeRx NB, to initiate a Phase 1 trial in a closely monitored clinical setting in the United States.RFK Jr. said the agency will prioritize therapies with Breakthrough Therapy designation, for which early evidence shows meaningful improvement over existing options for serious mental illness.The agency stated that its decision allows the study to proceed and does not mean the drug has been approved or found to be safe or effective. FDA added that it will continue to review data as it becomes available and support efforts to develop new treatments for alcohol use disorder and other mental health conditions.<a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is up 36% year-to-date,&nbsp;<a href="https://stocktwits.com/symbol/HELP">HELP stock</a> is down 33%, while&nbsp;<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is up 77%.The AdvisorShares Psychedelics ETF (PSIL) is up 68% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dan-ives-intel-comeback-rocky-balboa-ai-trade-in-third-innings/cZBWzYEReTv">Dan Ives Compares Intel's Comeback To Rocky Balboa, Says AI Trade Is In Its Third Innings — 'You Follow The Capex, That's Where Investors Are'</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

U.S. President Donald Trump signs an executive order on researching the effects of psychedelic drugs in medical treatment for veterans. (Photo by Allison Robbert/For The Washington Post via Getty Images)

FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

Equity

AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies

AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies PR Newswire BETHESDA, Md...

<ul class="summary-bullets"><li>Enveric stated that it intends to use the proceeds from the offering for product development, in addition to meeting its working capital and general corporate requirements.</li><li>The company stated that the gross proceeds from the offering are expected to be about $5 million.</li><li>Investors have an option to exercise Series I and short-term Series J warrants at a strike price of $2 per share, which would result in an additional fundraise of $8.9 million if fully exercised.</li></ul>Shares of Enveric Biosciences Inc. (ENVB) are on track for their worst decline in more than 10 weeks after the company announced the pricing of a $13.9 million offering.Enveric stated during after-market hours on Thursday that it has entered into definitive agreements to purchase and sell 2.2 million shares of its common stock at a purchase price of $2.25. This is at a discount of over 4% compared to Enveric’s closing price on Thursday.<a href="https://stocktwits.com/symbol/ENVB">Enveric shares</a> were down nearly 13% in Friday’s pre-market trade, and if the trend holds into the regular session, this will be the ENVB stock’s worst decline since January this year.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One user looked at the bright side of the private placement, noting that it helps the company secure funding for future growth.<stembedurl>https://stocktwits.com/MaximusRadius/message/650544419</stembedurl>Another user highlighted that Enveric’s offering has given the company enough money to survive.<stembedurl>https://stocktwits.com/Tigerz11/message/650553278</stembedurl><h2 class="st-heading-2">Why Did Enveric Raise Funds?</h2>Enveric stated that it intends to use the proceeds from the offering for product development, in addition to meeting its working capital and general corporate requirements.The company stated that the gross proceeds from the offering are expected to be about $5 million. Additionally, investors may exercise Series I and short-term Series J warrants at a strike price of $2 per share, exercisable immediately upon issuance.If these warrants are fully exercised on a cash basis, Enveric expects the gross proceeds to be approximately $8.9 million. The offering is expected to close on or about April 17, 2026.Enveric announced last month that it had secured a new U.S. patent for its EVM301 series of drug candidates. This series includes EB-003, which is currently under development for the treatment of mental health disorders.EB-003 is Enveric’s lead neuroplastogen, which the company says has the potential to address depression and anxiety without hallucinogenic effects. The company has so far secured 27 patents in the U.S. and currently has 60 pending applications across the U.S. and beyond.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 35% year-to-date and 84% over the past 12 months. The AdvisorShares Psychedelics ETF (PSIL) is up 72% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/el-erian-warns-economic-damage-iran-war-ai-death-of-washington-consensus/cZJvpAPRIDH">El-Erian Warns Economic Damage Due To Iran War Is Deepening — Says AI, Slow Death Of Washington Consensus Among Factors To Blame</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bear Market and falling chart - stock photo

ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat

Enveric stated during after-market hours on Thursday that it has entered into definitive agreements for the purchase and sale of 2.2 million shares of its common stock at a purchase price of $2.25.

<ul class="summary-bullets"><li>The company said that it is now in the process of completing pre-clinical studies for its lead candidate EB-003.</li><li>The company is looking forward to submitting an application to the FDA, seeking permission to commence human trials.</li><li>The drug is aimed at delivering fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.</li></ul>Shares of Enveric Biosciences (ENVB) fell 4% after hours on Friday on the heels of the company reporting wider loss for the fourth-quarter (Q4) of 2025 compared to the same period of the previous year.For Q4 2025, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260327524596/en/Enveric-Biosciences-Reports-Financial-Results-and-Provides-Corporate-Update-for-Fourth-Quarter-and-Fiscal-Year-Ended-2025">reported</a> a net loss of $4 million, higher than the loss of $3.2 billion reported for the corresponding quarter of 2024.<h2 class="st-heading-2">Plans Ahead</h2>The company said that it is now in the process of completing pre-clinical studies for its lead candidate EB-003.EB-003 is a non-hallucinogenic drug being developed for the treatment of underserved mental health conditions. The company is looking forward to submitting an application to the U.S. Food and Drug Administration seeking permission to commence human trials. In preclinical studies, the candidate showed potential in treating severe chronic depression, despair and post-traumatic stress disorder.“In 2026, we are working towards a streamlined IND application for EB-003 in preparation of the initiation of a first-in-human Phase 1 clinical trial. With the dual mechanism of action that engages both 5-HT2A and 5-HT1B receptors, we are optimistic that our research has the potential to profoundly impact mental health disease where innovation has been lacking for decades,” CEO Joseph Tucker said. The drug is aimed at delivering fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ENVB stock stayed within the ‘bearish’ territory at the time of writing while message volume rose from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> has lost nearly 90% of its value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

ENVB Stock Dips After-Hours On Widening Q4 Loss Despite Study Progress On Psychiatry Drug

For the fourth quarter of 2025, the company reported net loss attributable of $4 million, higher than the loss of $3.2 billion reported for the corresponding quarter of 2024.

<ul class="summary-bullets"><li>Incannex stated that its financial position is strong, with about $75 million in cash and no debt on its books.</li><li>The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.</li><li>Incannex is currently undertaking trials of IHX-42X and PSX-001 for the treatment of Obstructive Sleep Apnea and Generalized Anxiety Disorder, respectively.</li></ul>Incannex Healthcare Inc. (IXHL) on Friday announced that it has reactivated its share repurchase program, saying that it has been active over the past two trading days.The company cited a “significant disconnect” between its market capitalization and the underlying financial strength, as well as the progress it has achieved across its clinical programs.Incannex stated that it intends to continue utilizing the share repurchase program “opportunistically.”<a href="https://stocktwits.com/symbol/IXHL">Incannex Healthcare</a> shares gained more than 6% in Friday’s opening trade before paring some of the gains. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Incannex Touts Financial Strength</h2>The company stated that its financial position is strong, with about $75 million in cash and no debt on its books.“We are in a strong financial position to execute on our clinical development strategy while maintaining the flexibility to allocate capital in a disciplined and strategic manner,” said Incannex CEO Joel Latham.Incannex is currently undertaking trials of IHX-42X and PSX-001, its treatments for Obstructive Sleep Apnea (OSA) and Generalized Anxiety Disorder (GAD), respectively.The company stated that as of Dec. 31, 2025, it had approximately $18.5 million available for repurchases under the share repurchase program.<h2 class="st-heading-2">Incannex’s Obstructive Sleep Apnea Trial</h2>Incannex stated that Phase 2 clinical trials showed that IHX-42X’s lowest dose is the most effective for addressing OSA, reducing the Apnea-Hypopnea Index (AHI) by 51% compared with baseline. Incannex stated that one in four participants reported an 80% reduction in AHI.AHI is a key metric for gauging the severity of OSA, measuring how many apneas (complete breathing pauses) and hypopneas (partial airway blockages) occur per hour of sleep.The company said a global Phase 2/3 trial is currently underway to assess the efficacy and safety of IHL-42X.<h2 class="st-heading-2">Incannex’s Generalized Anxiety Disorder Trial</h2>The company noted that in the Phase 2 clinical trial of PSX-001 for the treatment of Generalized Anxiety Disorder (GAD), 44% of the participants who received the treatment reported a clinically meaningful or at least a 50% reduction in their anxiety scores.<a href="https://stocktwits.com/symbol/IXHL">IXHL stock</a> is down 68% year-to-date and 84% over the past 12 months. AdvisorShares Psychedelics ETF (PSIL) is up 35% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-gctk-stock-soaring-today/cZ3HcZMRIlU">GCTK Stock Is Soaring Pre-Market Today — What Is Fueling The Surge?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Incannex Healthcare Inc. logo is seen on a smartphone and in the background.

Incannex Reactivates Share Repurchase Program, Cites ‘Significant Disconnect’ Between Its Market Cap And Financial Strength

Incannex Healthcare - The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

IXHL Stock Gains As Incannex Reactivates Share Repurchase Program

The company stated that it intends to continue utilizing the share repurchase program “opportunistically.”

<ul class="summary-bullets"><li>The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01.</li><li>Relmada also announced that it has entered into a securities purchase agreement for a private investment in public equity financing, with gross proceeds of $160 million expected.</li><li>The company stated that it intends to use the proceeds for working capital and general corporate purposes, including advancing the research and development of its product candidates.</li></ul>Relmada Therapeutics Inc. (RLMD) shares soared more than 66% in Monday’s pre-market trade before paring some of the gains after the company announced an update in the Phase 2 trial of its bladder cancer treatment.Relmada stated that NDV-01 demonstrated a durable 76% complete response (CR) rate at 12 months, with 95% CR rate at any time in high-risk non-muscle invasive bladder cancer (NMIBC).<a href="https://stocktwits.com/symbol/RLMD">Relmada Therapeutics shares</a> were up nearly 38% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing.<h2 class="st-heading-2">What Do These Findings Signify?</h2>Relmada stated that its Phase 2 trial findings of NVD-01 demonstrated a 12-month CR rate of 80% in the BCG-unresponsive population. The company stated that this is one of the most difficult-to-treat segments of NMIBC.“We continue to observe strong responses in patients with BCG-unresponsive disease, with no progression to muscle-invasive disease and no patients requiring radical cystectomy,” said Relmada’s Chief Medical Officer-Oncology, Raj S. Pruthi.The company said that these interim results support advancement into the Phase 3 RESCUE registrational trial program to evaluate NDV-01.<h2 class="st-heading-2">What Is NDV-01?</h2>NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce) being developed to treat non-muscle invasive bladder cancer. It is designed to retain the drugs in the bladder and release them gradually over a 10-day period.NDV-01 comes ready to use and can be administered in about five minutes without anesthesia or specialized equipment. It is protected by patents through 2038.The company highlighted three upcoming milestones of NDV-01. It expects clearance for its Investigational New Drug (IND) application and the initiation of its Phase 3 RESCUE Program by mid-2026. The initial 3-month results from its Phase 3 2L BCG-unresponsive study are expected by the end of the year.<h2 class="st-heading-2">Relmada Announces $160 Million Financing</h2>Relmada also announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing, expecting gross proceeds of $160 million.The company stated that it intends to use the proceeds for working capital and general corporate purposes, including advancing the research and development of its product candidates.<a href="https://stocktwits.com/symbol/RLMD">RLMD stock</a> is up 24% year-to-date and 1,987% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iran-ceasefire-discussions-irrelevant-us-israel-want-to-fragment-country/cZdVSRXRIIX">Iran Says Ceasefire Discussions 'Irrelevant', Warns US And Israel Want To Fragment The Country: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

RLMD Stock Soars Pre-Market: Phase 2 Bladder Cancer Trial Data Impresses Investors

Relmada stated that the therapy showed a 76% complete response rate at 12 months in high-risk non-muscle invasive bladder cancer.

<ul class="summary-bullets"><li>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder.</li><li>Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company.</li><li>These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.</li></ul>Enveric Biosciences Inc. (ENVB) on Wednesday announced that Gilgamesh Pharmaceuticals has withdrawn a challenge against the company’s patent.Enveric stated that following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.<a href="https://stocktwits.com/symbol/ENVB">Enveric shares</a> were up more than 4% in Wednesday’s opening trade.<h2 class="st-heading-2">What Is The Patent In Question About?</h2>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).Gilgamesh filed a challenge against the patent in August 2025. Subsequently, AbbVie Inv. (ABBV) acquired bretisilocin from the company in a deal valued at up to $1.2 billion. Gilgamesh notified the U.S. Patent and Trademark Office (USPTO) that it had become a wholly-owned subsidiary of an entity owned by AbbVie.AbbVie filed a request with the USPTO in October to withdraw the post-grant review (PGR) petition filed by Gilgamesh.Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company. These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.Under its license terms, the company is eligible to receive aggregate upfront, development, and sales milestones potentially totaling up to $205 million, in addition to royalties on future sales.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user on Stocktwits termed the withdrawal of the petition against Enveric as “huge news.”<stembedurl>https://stocktwits.com/Luckyjs38/message/645825647</stembedurl><a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 39% year-to-date and 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-fda-accepts-imsidolimab-gpp-treatment/cZRyPfnRIGR">Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

<ul class="summary-bullets"><li>The trial was evaluating the efficacy and safety of SPL026 and enrolled 34 participants who had experienced depression for an average of 10.5 years.</li><li>The reductions in depressive symptoms were observed as early as one week following dosing and were sustained at three months, the company said.&nbsp;</li><li>Helus Pharma, however, said that the company is not advancing intravenous SPL026 in its current form.</li></ul> Shares of Helus Pharma (HELP) rallied 11% on Tuesday after the company announced positive results from its mid-stage clinical trial evaluating its experimental therapy SPL026 in participants with moderate-to-severe major depressive disorder.The trial was to evaluate the efficacy and safety of SPL026, and enrolled 34 participants who had experienced depression for an average of 10.5 years.The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.The reductions in depressive symptoms were observed as early as one week following dosing and were sustained at three months, with effects lasting up to six months in some participants, the company said. Further, no treatment-related serious adverse events were reported.<h2 class="st-heading-2">Executive Take Away</h2>“We have shown that a single dose of SPL026 is safe, effective and durable, with treatment effects comparable to other promising interventional treatments often requiring much longer treatment sessions.” said the study’s lead investigator Dr David Erritzoe.“Although such early trial results should always be interpreted with some caution, these data show the promise of DMT as a potentially more cost-effective treatment for clinical depression than related serotonergic agonists with longer psychoactive action due to the shorter dosing sessions,” they added<h2 class="st-heading-2">Other Pipeline Names</h2>Helus Pharma said that the company is not advancing intravenous SPL026 in its current form. However, the company will use the insights from the trial to inform its HLP004 development program. HLP004 is an experimental drug being studied in the treatment of generalized anxiety disorder. Data from a mid-stage study of HLP004 is expected in Q1 2026.The company is also developing experimental drug HLP003 as an adjunctive treatment for major depressive disorder.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HELP stock stayed within the ‘extremely bullish’ territory while message volume stayed at ‘high’ levels.“Time to buy more,” a Stocktwits user wrote while raising optimism for the GAD study data raising prices.<stembedurl>https://www.stocktwits.com/brunoq14/message/645159567</stembedurl>Another user, however, expects the stock to pare the gains made on Tuesday through the week.<stembedurl>https://www.stocktwits.com/ChristopherMcC/message/645124808</stembedurl><a href="https://stocktwits.com/symbol/HELP">HELP stock</a> has dropped 27% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/krys-stock-rallies-on-upbeat-earnings-jefferies-ups-price-target/cZRWvWzR4HT">KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’

The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.

<ul class="summary-bullets"><li>The company said that its COMP360 drug is the first classic psychedelic to consistently achieve a highly statistically significant result and a clinically meaningful effect.</li><li>Compass said that across both Phase 3 trials to date, COMP360 has demonstrated a generally well-tolerated and safe profile, with no unexpected safety findings.</li><li>The company added that a clinically meaningful reduction in MADRS of more than 25% was observed in a significant number of participants receiving the 25 mg dose in both COMP005 and COMP006 trials.</li></ul>Compass Pathways PLC (CMPS) shares were up more than 23% in Tuesday’s pre-market trade after the company announced that it had successfully achieved the primary endpoint in a Phase 3 clinical trial.Compass announced on Tuesday that its two Phase 3 trials have confirmed a highly differentiated profile for COMP360 for treatment-resistant depression (TRD).<h2 class="st-heading-2">Here Are Compass’ Findings</h2>The company said that its COMP360 drug is the first classic psychedelic to consistently achieve a highly statistically significant result and clinically meaningful effect, with a generally well-tolerated and safe profile.COMP360, a synthetic and proprietary formulation of psilocybin, is designed for TRD. Compass said that across both Phase 3 trials to date, COMP360 has demonstrated a generally well-tolerated and safe profile, with no unexpected safety findings.The company reported that in COMP006, two doses of COMP360 with a dose of 25 mg versus a dose of 1 mg demonstrated a highly statistically significant and clinically meaningful reduction in symptom severity as measured by the Montgomery-Asberg Depression Rating Scale (MADRS.)MADRS is a 10-item clinician-administered tool used to measure the severity of depressive episodes, ranging from 0 to 60. Compass said that the difference in the MADRS score between the 25 mg dose and the 1 mg dose was -3.8.The company added that a clinically meaningful reduction in MADRS of more than 25% was observed in a significant number of participants receiving the 25 mg dose in both COMP005 and COMP006 trials. Compass said that COMP005 participants witnessed a 25% reduction in MADRS, while the reduction stood at 39% among COMP006 participants.The company said that it has sought a meeting with the U.S. Food and Drug Administration (FDA) to discuss a rolling submission and review. It expects to complete a New Drug Application (NDA) submission in the fourth quarter (Q4).“These data strengthen our conviction in the highly differentiated profile for COMP360 and given the urgent need for new treatments in TRD, we are advancing our discussions with the FDA, with the goal of submitting an NDA in Q4 and securing approval,” said Compass CEO Kabir Nath.The company announced in January that the U.S. Food and Drug Administration (FDA) had accepted its Investigational New Drug (IND) application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), allowing the company to begin a late-stage trial.Compass said it is working on making COMP360 ready for commercial launch by the end of the year for TRD as well.<h2 class="st-heading-2">What Does Compass Do?</h2>London-headquartered Compass is a biotechnology company engaged in the development of solutions for mental health conditions through its investigational COMP360 synthetic psilocybin treatment.The company expects to release the 26-week Part B data from its COMP006 trial for TRD in the early third quarter (Q3) this year.<h2 class="st-heading-2">Here’s What Stocktwits Users Think</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/CMPS">Compass</a> trended in the ‘extremely bullish’ territory, with message volumes at ‘extremely high’ levels. The CMPS stock was the second most trending ticker on the platform at the time of writing.One bullish user called the trial results great, while adding that an FDA approval is “likely.”<stembedurl>https://stocktwits.com/Rocketzz/message/645094778</stembedurl>Another user called the results huge news, while saying, “just imagine what different dosing regimens could reveal with this safety profile.”<stembedurl>https://stocktwits.com/VikaDelic/message/645094710</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down 14% year-to-date, but up 27% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-david-solomon-warns-of-shocks-if-deficit-not-controlled/cZR5xtUR4t5">Goldman Sachs CEO David Solomon Warns Of 'Shocks' If Deficit Is Not Brought Under Control And Growth Rate Is Not Brought Up: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CMPS Stock Rises 23% Pre-Market As Compass Achieves Primary Endpoint In Phase 3 Treatment-Resistant Depression Trial

COMPASS Pathways is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

The company is currently conducting clinical trials of COMP360, a proprietary synthetic formulation of psilocybin, designed for treatment-resistant depression.

Best-Performing Active ETFs of 2025

Active ETFs shined in 2025 as GBUG, WGMI, PSIL, MKOR & LFSC delivered outsized gains amid gold, crypto and niche themes.

PSIL
AdvisorShares Psychedelics ETF

Feed

News

Sentiment

Fundamentals

Info

Latest PSIL News

PSILAdvisorShares Psychedelics ETF